



Andrew Bett, Ph.D. is a Senior Principle Scientist, in the Infectious Diseases and Vaccine Research Department at Merck Research Laboratories in West point, PA. Andrew earned his doctoral degree in virology and molecular biology from McMaster University, Hamilton, Ontario, Canada by developing adenoviral vectors focusing on their use a vaccine vectors against HIV. Andrew joined Merck in 1995 as a Postdoctoral Research Scientist in the Department of Human Genetics and became a full time Merck scientist in 1997. Andrew has worked on a number of viral vaccine programs during his 23 years at Merck including Merck's Adenovirus based HIV Vaccine which completed Phase 2 clinical trials and Merck's Dengue Virus Vaccine which is currently being evaluated in the clinic. Additional vaccine programs which Andrew has contributed to include programs on HSV and RSV. During his time at Merck Andrew has held positions of increasing responsibility, culminating in his current position leading the Vaccine Platforms Group that is responsible for preclinical evaluation of multiple vaccine platforms including mRNA based vaccines.